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Lymphocyte interactions with 
endothelial cells 
Yoji Shimizu, Walter Newman, Yoshiya 
Tanaka and Stephen Shaw 
Adhesion of lymphocytes to endothelium is vital to lymphocyte migration into 
lymphoid tissue and into inflammatory sites. In this review, Yoji Shimizu and 
colleagues identify the molecules that mediate lymphocyte-endothelial cell 
adhesion, describe the underlying principles of lymphocyte migration, and 
discuss a model of the sequence of events that allow a lymphocyte to successfully 
attach to endothelium and migrate into the surrounding tissue. 
Lymphocytes circulate throughout the body in the ongo- 
ing process of immune surveillance by traveling through 
the bloodstream, moving into tissue and then returning 
to the circulatory system via the lymphatics I~. Since 
lymphocyte recognition of, and response to, foreign anti- 
gen typically occurs in lymphoid organs or in non- 
lymphoid tissue, the principles and mechanisms that 
regulate lymphocyte movement into tissue are critical to 
the generation of an immune response. The interaction of 
lymphocytes with endothelial cells lining blood vessel 
walls represents the first critical step in lymphocyte 
movement into tissue. The role of endothelium as the 
gatekeeper regulating lymphocyte interactions with 
tissue is more complex than for other cells such as 
neutrophils and platelets, which bind to endothelium 
under an inflammatory crisis situation. Lymphocytes not 
only adhere strongly to inflamed endothelium and play a 
critical role in the inflammatory response s , but they also 
interact in a precisely regulated fashion with normal 
endothelium and thereby migrate into lymphoid and 
nonlymphoid tissue t-4. Here, the various molecules that 
mediate lymphocyte interactions with endothelial cells, 
and the underlying principles and mechanisms used by 
the immune system that allow this generally overlapping 
set of molecules to mediate both normal lymphocyte 
migration and influx into inflammatory sites, are re- 
viewed. Although the focus of recent studies has been on 
T-cell interactions with endothelium, earlier seminal 
work suggests that similar considerations apply to B 
cells 6. 
Lymphocyte and endothelial cell adhesion molecules 
The complexity of T-cell interactions with endo- 
thelium is illustrated by the multiplicity of molecules that 
mediate this cell-cell interaction. The large number of 
molecules that play some role in lymphocyte adhesion to 
either specialized endothelium in lymphoid organs (des- 
ignated high endothelial venules (HEV)) or activated 
endothelial cells (Table 1) can be divided into four 
groups. The list is limited to those molecules that have 
already been cloned and characterized at the molecular 
level. 
Selectins 
The three members of the selectin family of adhesion 
molecules (L-selectin, E-selectin and P-selectin) appear to 
play particularly important roles in mediating cell-cell 
adhesion in the vasculature 7. Selectins have a character- 
istic extracellular structural motif consisting of a lectin 
domain, a domain with homology to epidermal growth 
factor and a variable number of complement regulatory 
protein repeat sequences 7. Both L-selectin and E-selectin 
have been shown to be involved in T-cell adhesion to 
endothelium. L-selectin s,9 (also designated LECAM-1, 
MEL-14 and LAM-1) is expressed on a subset of T cells 
and has been extensively studied as the lymphocyte mol- 
ecule mediating homing to peripheral lymph nodes (see 
below). However, L-selectin also appears to be involved 
in both neutrophil and lymphocyte adhesion to acti- 
vated endothelial cells m-j5. E-selectin (also designated 
ELAM-1) is an inducible endothelial cell surface mol- 
ecule first described as mediating the adhesion of neutro- 
phils to activated endothelium 16; however, recent studies 
have shown that E-selectin also mediates the adhesion of 
a subpopulation of resting CD4 + memory T cells to 
activated endothelium 17,1~. 
Both E- and L-selectin bind to specific sialylated carbo- 
hydrates 19. Depending on the labeling conditions, the 
L-selectin ligand can be recognized on molecules of 50 
and 100 kDa (and several other less predominant species) 
by an L-selectin chimeric protein and a functionally 
inhibitory monoclonal antibody (mAb), MECA-79, that 
specifically stains peripheral lymph node HEV 2°,21. The 
HEV ligands for L-selectin and other putative homing 
receptors have been referred to as 'vascular addressins', 
signifying their role in mediating the tissue-specific 
adhesion of lymphocytes expressing the appropriate 
homing receptors. The ligands for E-selectin include 
sialyl Lewis X (sLeX), present on neutrophils and macro- 
phages, and a similar if not identical carbohydrate on a 
subset of memory T cells 1-3,t9. 
Integrins 
Integrins are a large family of cq8 heterodimeric cell 
surface proteins that are expressed on a wide variety of 
© 1992, Elsevier Science Publishers Itd, UK. 
Immunology Today 106 vo113 No..3 1992 
REVIEW 
Table 1. Molecules/pathways involved in lymphocyte adhesion to endothelial cells 
T-cell receptor Endothelial cell counter-reccpTor Role in 
Molecule F a m i l y  Molecule  F a m i l y  lncrcascd bx Traff ic  Inflammation 
intlammati{;n? 
Comments Refs 
L-sdectin SEL SgpS0, CHO Yes? Yes ~ Yes 
Sgp 100, 
MECAJ9 
sLeX- CHO E-selectin LEC Yes ;1~ Yes?" 
related 
structure 
LFA- 1 1NT ICAM- 1 lg Yes Yes? Yes 
LFA-1 INT ICAM-2 lg No Yes? Yes? 
VLA-4 INT VCAM-I lg Yes Yes? Yes? 
a4[3p/ INT : ~ ~ Yes? 
LPAM- l 
CD44 (L HA, CHO ~ Yes? Yes? 
MECA-3677 
HEBFL ~ ~ ~ ~ ~ Yes? 
Human ; ~ ; ~ Yes? 
HEBF 
HEBFI, I, ~ > ~ ~ Yes? ; 
Peripheral lymph node 8,10 
homing receptor, mediates 
neutrophil rolling 
Mediates binding of resting 17,1 
CD4 ~ memory T-cell subset 
Inflammation-induced ligand 22,24,26 
for strong adhesion 
Constitutive ligand for 22,24,33 
strong adhesion 
Pever's patch homing 23,28,29 
receptor in the mouse 
(designated LPAM-2) 
Pever's patch homing 2S 
receptor 
3 S-41 
Blocks binding to peripheral 42 
lymph node HEVs in rat 
Blocks binding to peripheral 43 
lymph node HEVs m human 
Blocks binding to mucosal 44 
HEVs in rat 
~'Yes' indicates in vivo functional evidence using either mAbs or soluble adhesion molecules; t,,?, indicates a current lack of existing in vitro or in vivo 
data implicating the interaction in the indicated adhesive function; "'Yes?' indicates a putative functional role based on i;z Htro mAb blocking studies; 
SEL: selectin; INT: integrin; lg: immunoglobulin supergene family; CHO: carbohydrate; CL: cartilage link proteil>; HA: hvaluronic acid. 
cell types and mediate adhesion to other cells and to 
components of the extracellular matrix (ECM) v. Both the 
leukocyte function-associated antigen 1 (LFA-1) and 
very late antigen 4 (VLA-4) integrins play major roles in 
T-cetl adhesion to activated endothelium by binding their 
respective cell surface ligands, intercellular adhesion 
molecule 1 (1CAM-l) and ICAM-2 (for LFA-1) and 
vascular cell adhesion molecule 1 (VCAM-I) (for 
VLA-4) -'2-~'4. LFA-1 is expressed by all T cells, but at one- 
to twofold higher levels by memory cells than by naive 
cells 2s. LFA-1 is involved in lymphocyte trafficking, but 
its role appears to be one of general non-organ-specific 
strengthening of adhesion 2~. VLA-4 shows a much more 
heterogeneous pattern, with low expression on most 
naive cells and very heterogeneous expression on mem- 
ory T cells (Ref. 27 and K.J. Horgan et al., unpublished). 
In the mouse, two integrin molecules, lymphocyte Peyer's 
patch HEV adhesion molecule 1 (LPAM-1) and 
LPAM-2, each composed of the VLA-4 e~ chain but with 
distinct 13 chains, have been implicated as receptors me- 
diating lymphocyte migration to mucosal lymphoid or- 
gans, such as Peyer's patcheseS: LPAM-2 is homologous 
to human VLA-4; LPAM- 1 consists of the VLA-4 c~ chain 
associated with a distinct [3 chain, designated [3p 2s. While 
VLA-4 binds to VCAM-I on cultured activated endo- 
thelial cells '-:<>, the relationship of the LPAM-1/2 ligand 
on Peyer's patch HEVs to VCAM-1 is not known; one 
study in humans has failed to detect VCAM-I on 
mucosal HEVs ~°. VLA-4 is also one of two integrin fibro- 
nectin receptors on T cells 2s,~l and inhibition of lympho- 
cyte adhesion to rat high endothelial cells by peptides 
containing the VLA-4 recognition sequence on fibro- 
nectm suggests a possible role for ECM molcculcs in 
lymphocyte-endothelial cell adhesion ~-' 
lmmunoglobul in  supergene family 
Three members of the immunoglobulin supergene 
family are involved in T-cell-endothelial-cell inter- 
actions, namely ICAM-1, ICAM-2 and VCAM-I. They 
serve as endothelial cell surface ligands for tile LFA- 1 and 
VLA-4 integrins. Differential regulation of ICAM-1, 
ICAM-2 and VCAM-1 expression plays a critical role m 
the use of these various adhesion pathways by T cells. 
ICAM-2 is constitutively expressed at a high level on 
resting endothelial cells and its expression is not aug- 
mented bv acti~ation~L In contrast, ICAN/-I is weakly 
expressed and VCAM-1 is absent on resting cndo- 
thelium, but the expression of each is rapidly increased by 
endothelial cell activation 2-',24,~4. 
CD3 1, another lg supergene family member, is postu- 
lated to mediate platelet-endothelial-cell adhesion ~s. 
CD31 is strongly expressed, not only on HEVs, but also 
on a subset of T cells that are predominantly naive T cells 
(Y. Tanaka et aI., submitted). CD31 may mediate ad- 
hesion through a homophilic interaction~L and recent 
data suggest a critical role for CD31 m regulating 
adhesion of unique T-cell subsets to cndothelium (Y. 
Tanaka et al., submitted and see below). 
Other  molecules 
The CD44 molecule is a widely expressed cell surface 
protein with structural homology to cartilage link pro- 
teins~2 CD44-specific mAbs have been shown to inhibit 
lymphocyte binding to HEVs ~s and activated endothelial 
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cells 39. CD44 binds to the glycosaminoglycan, hyalu- 
ronic acid, and CD44 binding to some cultured endo- 
thelial cells can be blocked by treatment of these cells 
with hyaluronidase 4°. However, other studies have 
shown that binding to HEVs is not inhibited by soluble 
hyaluronic acid or hyaluronidase treatment of HEVs 41, 
suggesting that CD44 may bind to additional ligands, 
such as the mucosal vascular addressin defined by the 
MECA-367 mAb 4. The other molecules listed in Table 1 
define antigens recognized by mAbs that block adhesion 
to HEVs in various species 42-44. The relationship of these 
antigens to the more well-defined molecules discussed 
above remains to be determined. 
Fundamental principles of T-cell migration 
The functions of T cells require their incessant move- 
ment. The simplest traffic pattern would be random 
migration of all T cells through all tissues. Instead, 
evolution has made the process more efficient by routing 
T cells in different ways according to multiple cues. For 
the purposes of this discussion, the differential migration 
of T cells in normal, healthy individuals is termed traf- 
ficking or 'homing'. Four governing principles regulate 
T-cell trafficking: (1) each lineage of immune cells will 
have distinct rules governing its migration; (2) naive T 
cells migrate into lymph nodes, while memory T cells 
migrate primarily into nonlymphoid tissue; (3) memory 
cells become biased to preferentially home to tissues 
related to the one in which they were previously stimu- 
lated; and (4) inflammation augments the influx ofT cells 
and reduces the selectivity that governs normal homing. 
Cell-lineage specific migration 
Cells of different lineages (for example T cells versus 
neutrophils versus platelets) differ in their interactions 
with endothelial cells; this results in distinct patterns of 
migration 6. In addition, subsets within each lineage, such 
as CD4 + and CD8 + T cells, also exhibit differences in 
their movement through the body 4s. Further phenotypic 
differences between CD4 + and CD8 + T cells that would 
be expected to influence interactions with endothelium 
also exist. For example, a higher proportion of CD8 + 
than CD4 + circulating T cells express CD45RA (thought 
to be a marker of naive T cells), LFA- 1, VLA-4 and CD31 
(Ref. 46 and Y. Tanaka et al., submitted). 
Differential migration of naive and memory T cells 
Within the CD4 ÷ T-cell lineage, the most fundamental 
distinction among subsets is between naive cells (which 
have not been stimulated by antigen after export from the 
thymus) and memory cells 24,2s,47 49; CD45RA is cur- 
rently the best marker of naive cells and CD45RO of 
memory cells. Although the body of experimental data is 
much less complete, CD45RA/CD45RO also subdivides 
CD8 + T cells and may reflect a similar functional dichot- 
omy 4~'5°'sl. Naive and memory T cells have radically 
different trafficking patterns 47. Virtually all the T cells 
found in tissues such as skin 52, gut lamina propria -s3 and 
on bronchial surfaces 54 are of the memory phenotype. 
Thus, memory cells preferentially migrate into both nor- 
mal and inflamed nonlymphoid tissue. Conversely, naive 
T cells account for most of the torrent of cells entering 
lymph nodes 4s. This well-known concept of selective 
lymphocyte trafficking 6,47,55 makes good sense, since the 
lymph node serves as a specialized site that brings to- 
gether the rare relevant naive T cells, specialized antigen- 
presenting cells (APCs), and the antigen load drained 
from local tissue in a microenvironment particularly 
suited to T-cell stimulation. 
Dramatic progress has been made in understanding the 
molecular basis for this fundamental difference in mi- 
gration pattern. Memory CD4 + T cells express higher 
levels of several adhesion molecules than do naive CD4 + 
T cells25; the enhanced expression of LFA-I, VLA-4, 
VLA-5 and VLA-6 on memory cells is associated with 
their increased capacity to bind to the relevant ligands 
ICAM-I, VCAM-1, fibronectin and laminin-'L More 
recently, expression of a carbohydrate epitope expressed 
on a memory T-cell subset that binds to E-selectin has 
been described (Ref. 18 and Y. Shimizu, unpublished). 
More memory cells than naive cells bind to endothelial 
cells in vitro24,s6-ss; this binding is mediated by VLA-4, 
LFA-1 and the E-selectin-binding carbohydrate present 
on a subset of memory cells 17,1s,-'4. Thus, there is a 
striking correlation between in vitro studies of T-cell 
binding to cultured endothelial cells and in vivo findings 
regarding memory T-cell interaction with endothelium 
from nonlymphoid organs. 
Which molecules mediate the preferential migration of 
naive T cells into lymph nodes by interaction with periph- 
eral lymph node HEVs? In the mouse, assays of T-cell 
binding to HEVs in frozen lymph node sections and mAb 
blocking of in vivo migration o f t  cells i-4 have implicated 
L-selectin, which is expressed on all naive T cells and a 
subset of memory T cells 27. We suggest that CD31 may 
also be involved in preferential naive and CD8 + T-cell 
interaction with HEVs, since CD31 can potently induce 
integrin-mediated adhesion. Like L-selectin, CD31 is 
preferentially expressed on naive T cells (Y. Tanaka etal., 
submitted). 
There's no place like home 
The third principle governing T-cell Interaction with 
endothelium is that memory T cells are further sub- 
divided into subpopulations that preferentially migrate 
into particular anatomic sites. Memory T cells are biased 
to return to the tissue in which they were originally 
stimulated; this makes sense as an evolutionary strategy 
since T cells are most likely to re-encounter an antigenic 
threat in the same (or similar) anatomic location 27,47. It is 
considered that there is a substantial number of anatom- 
ical compartments served by specialized T-cell subsets, 
including gut 2s, synovium s9 and skin is. The experimen- 
tal basis for this hypothesis comes from studies in which 
the fate of tagged lymphocytes derived from different 
anatomic sites was monitored following re-introduction 
into the host. These data, complemented by the recent 
understanding of naive and memory cells, clearly estab- 
lish tissue-specific migratory patterns 1~. Such homing 
patterns are, presumably, the result of specific pairs of 
molecules on T cells and endothelial cells that confer 
regional specificity. For gut homing, the integrins 
LPAM-1 and LPAM-2 are thought to interact with an 
undefined ligand on Peyer's patch HEVs; this inference is 
based on functional inhibition by relevant mAbs of 
tissue-specific binding of selective T-cells with Peyer's 
Immunology Today 108 ro t  13 No. 3 1992 
REVIEW 
patch endothelium -'s. Similar studies have implicated 
other endothelial molecules in homing to peripheral 
lymph nodes (via L-selectin) and mucosal sites (possibly 
via CD44). Molecules that might mediate homing under 
normal, noninflammatory conditions to other anatomic 
sites, such as the skin and lung, remain poorly defined. 
A number of aspects of homing into tissue warrant 
comment. First, tissue specificity is undoubtedly relative, 
not absolute; for example, putative skin-homing cells can 
ahnost certainly migrate elsewhere, particularly under 
conditions of inflammation. Second, the specificities for 
different anatomic sites are probably determined m a 
combinatorial fashion by multiple receptors, not exclus- 
ively by a single receptor. Third, we predict that there is 
much more diversity among memory T cells than is 
currently appreciated and that they are in effect an "army 
of specialists' that interact well with a limited number of 
the large range of specialized microenvironments 5'. 
Fourth, early models of T-cell differentiation proposed 
that naivc cells have a full complement of homing recep- 
tors, with loss of the irrelevant ones during differen- 
tiation. The data now suggest that, in some cases, the 
receptor on the relevant memory cell subset, such as the 
carbohydrate-mediating binding to E-selectin, is not 
used/expressed bv naive cells ~-. 
Inflammation increases adhesion and reduces the 
selectivity of trafficking 
The fourth principle governing T-cell interaction with 
endothelium is that it is dramatically modified by inflam- 
mation. The fundamental change is in the phenotype of 
thc endothelial cell. The change can result from a very 
wide range of stimuli, including 'alarm cytokines', such 
as interleukin 1 (IL- I) and tumor necrosis factor (TNF), 
that are released/secreted by a wide variety of cell types, 
and lymphokines, such as IL-4 and gamma-interferon, 
derived from T cells that have encountered their specific 
antigen-,-':,-' <~4,,,0.~1. The expression of endothelial ligands 
for T-call binding is either increased (typically the 
case for ICAM-1) or induced de novo (typically the case 
for VCAM-I and E-selectm). The specific patterns of 
cndothelial cell ligand expression are complex and de- 
pend on: (1) the inducing cytokine or combination of 
cytokines; (2) the time after cytokine exposure; and (3) 
the type of endothelial cell and its environmental cues 
from neighboring ceils and the ECM. Such ligand induc- 
tion by cytokmes occurs m vitro, and can be observed in a 
wide variety of natural and experimental inflammatory 
lesions in vi~'o ~'<~' ~. The major consequence of this change 
in endothelial cell phenotype is increased efficiency of 
T-cell binding, particularly of memory T cells. It is note- 
worthx that T-cell adhesion molecules that are thought to 
mediate tissue-specific homing under normal conditions, 
such as L-selectin and VLA-4, also contribute to T-cell 
adhesion to inflamed endothelium s,le,z~,z4,s-'. This 
suggests that expression of many of the ligands that 
contribute to normal lymphocyte homing can be induced 
by inflammation at sites where they are not normally 
expressed. We surmise that the immune system can af- 
ford refined regional strategies under conditions of nor- 
mal surveillance, but mobilizes many of these same 
molccular interactions for widespread use when a state of 
emergency exists in a tissue. Conversely, other molecules 
that are currently considered to function only under 
inflammatory conditions, such as E-selectin, may also 
play a role in normal lymphocyte trafficking (W, 
Newman, unpublished). Inflammation not only influ- 
ences the influx of memory cells into nonlymphoid tissue, 
but also dramatically increases lymphocyte (presumably 
naive T cells) entry into lymph nodes~L 
The adhesion cascade 
Lymphocyte adhesion to endothelial cells clearly in- 
volves multiple receptor-ligand interactions. For 
example, at least five distinct receptor-ligand inter- 
actions have been implicated in the binding of CD4 ~ T 
cells to activated endothelial cells: LFA-I (to ICAM-I 
and ICANI-2), VLA-4 (to VCAM-I), E-selectin and 
CD44 (Refs 22-24,39 and Table 1). The potential advan- 
tages of the use of multiple adhesion interactions are clear 
when it is realized that the goal at an inflammatory site is 
to rapidly and efficiently capture a large number ot 
lymphocytes from the blood. The overall strength of 
adhesion can be amplified with the use of multiple 
receptor-ligand interactions, each of which individually 
may provide only minimal adhesive strength under 
physiological conditions of flow in a vcnulc. 
An additional functional rationale for the use of mul- 
tiple adhesion molecules in lymphocyte-endothelial-cell 
interactions is that each receptor-ligand pair may pro- 
vide a distinct and unique function that is necessary for 
adhesion to, and migration through, endothelium. Thus, 
lymphocyte adhesion to endothelium mav revolve an 
"adhesion cascade', defined as the sequential, temporal 
use of various adhesion molecules during the entire pro- 
cess, from initial attachment to the final entry of lympho- 
cytes into the surrounding tissue. The i*est known 
enzymatic cascades, clotting and complement, demon- 
strate amplification and regulation. Recent studies of 
platelets and neutrophils (Refs 14,15,64-66 and G. Zim- 
merman, this issue), coupled with the existing data on T 
cells, suggest an adhesion cascade in T-cell interactions 
with endothelium. We propose a model involving the 
following sequence of events: (1) multiple random colli- 
sions with the endothelmm and establishment of a tenu- 
ous, unstable interaction, (2) delivery of a triggering 
signal that actixates T-cell integrin function, (3) estab- 
lishment of strong adhesion to the endothelium and (4) 
subsequent migration to endothelial junctions and trans- 
migration into the surrounding tissue (Fig. I). 
Step 1 - initial interaction between T cell and endothelium 
There are two points to consider here. First, in contrast 
to many cartoons of endothelial cells that show a smooth 
surface of flattened cells, endothelial cells, particularly 
HEVs, have a rough surface morphology that is charac- 
terized by clefts and interfacing networks among the 
cells~C,'% This endothelial morphology has two import- 
ant consequences: it increases the overall endothelial cell 
surface area, and it modifies thc flow from laminar to 
tubular. Under normal circumstances, the slowest flow 
rates in the circulatory tree occur in the post-capillary 
venules; these would therefore be expected to be (and 
are) the normal site for lymphocyte interaction with 
endothelium. Furthermore, at an inflammatory site, the 
blood flow rate is reduced ()wing to vessel dilation. All of 











Fig. 1. The proposed sequence of events in an adhesion cascade mediating T-cell adhesion to endothelium is shown. The cascade inw)lves: 
(a) tenuous adhesion or tethering of a flowing T cell via selectin-mediated interactions; (b) delwery of a triggering signal to upregulate 
integrin function; (c) strong integrin-mediated adhesion; and (d) migration of the T cell through the endothelium into the surrounding 
tissue. Potential candidate receptor-ligand interactions involved in each step of the cascade are indicated; however, additional molecules 
may also be involved at each step and the use of specific adhesion pathways is probably dependent on the type o f t  cell and endothelial cell 
involved. 
these factors result in increased opportunities for a pass- 
ing lymphocyte to interact with endothelium. At least in 
the one tissue studied, lymphocytes, unlike neutrophils, 
do not exhibit rolling behavior; analysis of lymphocyte 
interactions with Peyer's patch HEVs show that many of 
the lymphocytes entering the postcapillary venule collide 
more than once with the endothelium and rapidly stop 69. 
Second, the majority of lymphocytes in the circulation 
are in a resting state. Thus, it is unlikely that integrins 
such as LFA-1 and VLA-4 play a major role in the initial 
adhesion, since T-cell integrins require an activation 
signal to mediate strong binding 7,2s,7°,71. This is further 
supported by findings that integrins on activated T cells 
do not bind well to ICAM-1 and fibronectin under 
physiological shear forces 64. The selectins, including 
L-selectin and E-selectin, are the best candidates for 
initiating adhesion since both L-selectin and E-selectin 
mediate adhesion of resting T cells to endothelium 12,t7, 
and selectins have been shown to mediate adhesive inter- 
actions of neutrophils under flow conditions 14,15,64. The 
apparently unique ability of selectins to initiate adhesion 
may relate to the rapid reaction rate of the carbohydrate- 
lectin interactions that they exploit 72. We do not discount 
the potential involvement of other adhesion molecules, 
such as CD44. Furthermore, under conditions of disease 
or inflammation, additional molecules may also con- 
tribute to this initial interaction because of disease- 
associated activation events that result in changes in 
T-cell adhesion molecule phenotype and/or function7L 
Step 2 - triggering 
Integrins on resting T cells mediate strong adhesion 
only when the cell receives the right activating stimulus. 
Recent studies suggest that a number of T-cell surface 
molecules can induce signals that activate T-cell integrin 
function: the CD3-T-cell receptor, CD2, CD7, CD28, 
CD31 and VLA-4 (Refs 7,25,70,71,74,75). Which of 
these (or other) molecules might act as a trigger during 
T-cell interaction with endothelium? CD31 is a promis- 
ing candidat~ to provide this trigger function for CD31 + 
T cells, which are predominantly naive T cells. Anti- 
CD31 mAb perturbation of CD8 + naive T cells results in 
a rapid induction of integrin function, particularly 
VLA-4 (Y. Tanaka et al., submitted). Since CD31 is 
considered to participate in homophilic (and potentially 
heterophilic) interactions 36, CD31 (and potentially other 
ligands) on endothelial cells would engage CD3l on T 
cells and, thereby, trigger integrin-mediated adhesion; 
this is consistent with in vitro studies that show T-cell 
adhesion to purified CD31 (Y. Tanaka et al., submitted). 
VLA-4 is also a candidate to amplify its own adhesion, 
since mAb ligation induces functional activation (Refs 
76,77). Thus, weak binding of VLA-4 to VCAM-1 on the 
endothelium could provide a feedback loop to augment 
integrin adhesion. Such integrin autoregulation by ligand 
has recently been reported for the platelet integrin gplIb- 
llIa TM. VLA-4, like CD31, is well expressed only on some 
T cells and therefore its postulated triggering function 
would, likewise, be subset specific. 
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Although there is no evidence yet to implicate CD2, 
CD7 or CD28 in triggering endothelial adhesion, antigen 
recognition via the CD3-T-cell receptor, in triggering 
mtegrin function, may play a role in the context of 
allogeneic organ transplantationTL E-selectin is also a 
candidate triggering molecule, since E-selectin appears 
to regulate Mac-I function on neutropbils~5,"<'; similar 
regulation of integrin function on T cells by E-selcctin has 
not been reported. Although chemoattractants present at 
endothelial cell junctions have been proposed to result in 
upregulation of integrin function on neutrophils "s, sol- 
uble mediators such as cytokines have not been found to 
modulate integrin function on T cells (Y. Shimizu and 
G.A. wm Seventer, unpublished). 
Step .7 - strong adhesion to endothelium 
Integrins, once their function is induced, undoubtedly 
play a major role as the main adhesive force or 'glue' that 
T cells use to stick to endothelium. It is presumably this 
strong adhesion that can rapidly bring flowing T cells to 
a halt'% The predominant pathways are thought to be 
VLA-4-VCAM- 1, LFA- 1-1CAM- 1 and LFA-1-ICAM-2 
(Refs 22-24,39). It is likely that other integrins, such as 
LPAM-I, also contribute in interactions with Peyer's 
patch HErs  -'s. 
Step 4 - migration to the endothelial cell junction and 
transmigratiolz 
Migration of the T cell into tissue requires arrest of 
the T cell by the endothelium and transendothelial mi- 
gration. This requires a reduction in adhesion, followed 
by orderly migration. Several mechanisms may contrib- 
ute to reduction in adhesion. The first is the transience of 
augmented integrin function. Signals via molecules such 
as CD3 (Refs 7,25,70) and CD31 (Y. Tanaka, un- 
published) induce integrin function which then decays 
rapidly. Although the mechanism that accounts for this 
transience is not known, the end result will be to allow 
the I cell to move r<'. The second mechanism demon- 
strated for T cells is shedding; L-selectin is shed following 
T-cell activation s{~, and this may occur during interaction 
with endothelial cells to release the T cell to migrate. 
Although in vitro migration assays have demonstrated 
inhibition of T-cell migration through endothelial mono- 
layers by LFA-I and CD44 mAbs 39 and decreased mi- 
gratory capacity of T-cell clones deficient in LFA-I 
expression sl, the precise role that these and other mol- 
ecules play in the complex process of migration awaits 
further investigation. 
Several features of this model warrant comment. First, 
since deliver) of a partial activation signal is essential to 
the cascade, the T cell entering the surrounding tissue 
may be uniquely suited to respond vigorously to foreign 
antigen cncountered on antigen-presenting cells. The 
ability of purified ligands, such as ICAM-1 and 
VCAM-I, to facilitate T-cell proliferative responses in 
vitro is consistent with this interpretation"2,sL Second, 
we consider that the overall sequence of events will bc 
similar, regardless of whether interaction with normal 
HEVs or inflamed endothelium is occurring. Third, the 
specificity of the T-cell interaction with endothelium is 
conferred not by a single molecule but by the entire 
cascade, Many of the T-cell surface molecules inw)lved 
arc present only on a subset ofT cells and the ligands are 
restricted to certain endothelia. Thus, a CD8 + naive T 
cell interacting with lymphoid tissue HEVs may use 
L-selectm for the first step, CD31 for the second and 
VLA-4 for the third; in contrast, a CD4 ~ memory T cell 
interacting with inflamed endothelium might use E- 
selectin for the first, VLA-4 for the second and VLA-4 and 
LFA-1 for the third. Fourth, this model has relevance to 
the current interest in developing therapeutic reagents 
that modulate T-cell-endothelial cell adhesion, since it 
predicts that inhibition of any step in the cascade should 
result in inhibition of migration into tissue. Furthermore, 
the use of a generally overlapping set of molecules in 
trafficking and inflammation suggests that the thera- 
peutic value of any of these reagents must be weighed 
against their cffects on normal lymphocyte homing. 
Although many questions regarding the validity of this 
model remain to be answered, it neverthcless provides an 
important framework for the development of hypotheses 
that can be tested. The continued interest m lymphocyte- 
endothelial-cell interactions will undoubtedly lead to a 
further understanding of the molecules and mechanisms 
that mediate this critical ccll-cell interaction. 
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